Results 21 to 30 of about 734,704 (283)

Immunomodulatory treatment of interstitial lung disease

Therapeutic Advances in Respiratory Disease, 2022
Interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) have an array of immunomodulatory treatment options compared with IPF, due to their inflammatory component.
L. van den Bosch, F. Luppi, G. Ferrara, M. Mura   +3 more
semanticscholar   +1 more source

A multidisciplinary approach to the diagnosis of antisynthetase syndrome

Frontiers in Medicine, 2022
Antisynthetase syndrome is a subtype of idiopathic inflammatory myopathy, strongly associated with the presence of interstitial lung disease. Diagnosis is made by identifying myositis-specific antibodies directed against aminoacyl tRNA synthetase, and ...
Matthew Wells, Sughra Alawi, Kyaing Yi Mon Thin, Harsha Gunawardena, Harsha Gunawardena, Adrian R. Brown, Anthony Edey, John D. Pauling, John D. Pauling, Shaney L. Barratt, Huzaifa I. Adamali   +10 more
doaj   +1 more source

Variability in Global Prevalence of Interstitial Lung Disease

Frontiers in Medicine, 2021
There are limited epidemiologic studies describing the global burden and geographic heterogeneity of interstitial lung disease (ILD) subtypes. We found that among seventeen methodologically heterogenous studies that examined the incidence, prevalence and
B. Kaul, V. Cottin, H. Collard, C. Valenzuela   +3 more
semanticscholar   +1 more source

Differentiating interstitial lung diseases from other respiratory diseases using electronic nose technology

Respiratory Research, 2023
Introduction Interstitial lung disease (ILD) may be difficult to distinguish from other respiratory diseases due to overlapping clinical presentation. Recognition of ILD is often late, causing delay which has been associated with worse clinical outcome ...
Iris G. van der Sar, Marlies S. Wijsenbeek, Gert-Jan Braunstahl, Jason O. Loekabino, Anne-Marie C. Dingemans, Johannes C. C. M. In ‘t Veen, Catharina C. Moor   +6 more
doaj   +1 more source

Predictors and changes of physical activity in idiopathic pulmonary fibrosis

BMC Pulmonary Medicine, 2022
Background Different clinical predictors of physical activity (PA) have been described in idiopathic pulmonary fibrosis (IPF), but studies are lacking evaluating the potential role of muscle strength and anxiety and depression symptoms in PA limitation ...
Diana Badenes-Bonet, Anna Rodó-Pin, Diego Castillo-Villegas, Vanesa Vicens-Zygmunt, Guadalupe Bermudo, Fernanda Hernández-González, Karina Portillo, Juana Martínez-Llorens, Roberto Chalela, Oswaldo Caguana, Jacobo Sellarés, Maria Molina-Molina, Xavier Duran, Joaquim Gea, Diego Agustín Rodríguez-Chiaradia, Eva Balcells   +15 more
doaj   +1 more source

Mass spectrometry detection of inhaled drug in distal fibrotic lung [PDF]

, 2022
BACKGROUND: Currently the only available therapies for fibrotic Interstitial Lung Disease are administered systemically, often causing significant side effects.
Cahn, A, Cui, Y, Jarvis, E, Marshall, P, Mikolasch, TA, Oballa, E, Porter, JC, Sahota, J, Terry, RL, Thakrar, R, Vahdati-Bolouri, M   +10 more
core   +1 more source

Clinicoserological features of antisynthetase syndrome (ASyS)-associated interstitial lung disease presenting to respiratory services: comparison with idiopathic pulmonary fibrosis and ASyS diagnosed in rheumatology services

BMJ Open Respiratory Research, 2021
Introduction Antisynthetase syndrome (ASyS) is a rare autoimmune connective tissue disease (CTD), associated with autoantibodies targeting tRNA synthetase enzymes, that can present to respiratory (interstitial lung disease (ILD)) or rheumatology ...
Harsha Gunawardena, Huzaifa I Adamali, Havra H Adamali, Caroline Cotton, Ben Mulhearn, Hina Iftikhar, John David Pauling, Lisa Spencer   +7 more
doaj   +1 more source

Lung function trajectory in progressive fibrosing interstitial lung disease

European Respiratory Journal, 2021
Background Proposed criteria for progressive fibrosing interstitial lung disease (PF-ILD) have been linked to increased mortality risk, but lung function trajectory after satisfying individual criteria remains unknown. Because survival is rarely employed
J. Oldham, Cathryn T. Lee, Zhe Wu, W. S. Bowman, J. V. Pugashetti, Nam Dao, J. Tonkin, Hasan Seede, G. Echt, A. Adegunsoye, F. Chua, T. Maher, C. Garcia, M. Strek, C. Newton, P. Molyneaux   +15 more
semanticscholar   +1 more source

Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry

European Respiratory Journal, 2021
Pulmonary hypertension (PH) is a common complication of many chronic lung diseases, especially COPD and interstitial lung disease (ILD) [1]. In these conditions, the development of PH is associated with an aggravation of symptoms and an increase in ...
K. Olsson, M. Hoeper, C. Pausch, E. Grünig, D. Huscher, D. Pittrow, S. Rosenkranz, H. Gall   +7 more
semanticscholar   +1 more source

Multimodality Imaging in Connective Tissue Disease-Related Interstitial Lung Disease [PDF]

, 2021
Interstitial lung disease is a well-recognised manifestation and a major cause of morbidity and mortality in patients with connective tissue diseases. Interstitial lung disease may arise in the context of an established connective tissue disease or be ...
Bilhim, T, Borba, A, Fernandes, O, Grafino, M, Irion, K, Moraes-Fontes, MF, Pinheiro, S, Ruano, C, Silva, S   +8 more
core   +1 more source